Bank of America’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-204,100
| Closed | -$2.52M | – | 8468 |
|
|
2022
Q4 | $2.52M | Sell |
204,100
-17,800
| -8% | -$252K | ﹤0.01% | 4047 |
|
|
2022
Q3 | $3.1M | Buy |
221,900
+149,700
| +207% | +$2.41M | ﹤0.01% | 3877 |
|
|
2022
Q2 | $997K | Buy |
+72,200
| New | +$1.16M | ﹤0.01% | 4913 |
|
|
2020
Q1 | – | Sell |
-17,000
| Closed | -$2.11M | – | 7370 |
|
|
2019
Q4 | $2.11M | Buy |
+17,000
| New | +$1.52M | ﹤0.01% | 3988 |
|
|
2018
Q2 | – | Sell |
-130,000
| Closed | -$8M | – | 7396 |
|
|
2018
Q1 | $8M | Buy |
+130,000
| New | +$7.83M | ﹤0.01% | 2625 |
|
|
2017
Q4 | – | Sell |
-8,500
| Closed | -$493K | – | 7324 |
|
|
2017
Q3 | $493K | Hold |
8,500
| – | – | ﹤0.01% | 4958 |
|
|
2017
Q2 | $1.03M | Sell |
8,500
-84,000
| -91% | -$9.73M | ﹤0.01% | 4414 |
|
|
2017
Q1 | $10.5M | Buy |
92,500
+14,000
| +18% | +$1.63M | ﹤0.01% | 2334 |
|
|
2016
Q4 | $8.53M | Buy |
78,500
+8,500
| +12% | +$1.01M | ﹤0.01% | 2448 |
|
|
2016
Q3 | $11.5M | Buy |
70,000
+15,100
| +28% | +$2.38M | ﹤0.01% | 2105 |
|
|
2016
Q2 | $7.83M | Buy |
54,900
+36,500
| +198% | +$5.32M | ﹤0.01% | 2428 |
|
|
2016
Q1 | $2.36M | Buy |
+18,400
| New | +$2.17M | ﹤0.01% | 3425 |
|
|
2014
Q2 | – | Sell |
-600
| Closed | -$198K | – | 8268 |
|
|
2014
Q1 | $198K | Buy |
+600
| New | +$202K | ﹤0.01% | 5447 |
|
Bank of America's ICPT Position: Q4 2023 in Review
Bank of America sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 402,359 shares — an estimated $7.46M sold.
Bank of America first reported a position in ICPT in Q2 2013 and held it in 42 quarters. The position peaked at $66.7M in Q3 2016. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.
- Bank of America reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
- Bank of America sold 402,359 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $7.46M.
- Bank of America first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2013 and held it in 42 quarters.
- Bank of America's Intercept Pharmaceuticals, Inc. position peaked at $66.7M in Q3 2016.
- 0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.
Based on Bank of America's 13F filing for Q4 2023, filed 14 Feb 2024.